Compile Data Set for Download or QSAR
Report error Found 1808 Enz. Inhib. hit(s) with Target = 'Cystic fibrosis transmembrane conductance regulator'
TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221982(US9303035, 6)
Affinity DataIC50: 0.0500nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221986(US9303035, 8.0a)
Affinity DataIC50: 0.0700nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221984(US9303035, 7.0a)
Affinity DataIC50: 0.0900nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221987(US9303035, 8.1a)
Affinity DataIC50: 0.120nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM301431(BDBM301432 | US10131670, Example 14 | 4-amino-7-{1...)
Affinity DataEC50:  0.200nMAssay Description:Primary cystic fibrosis human bronchial epithelial (CF hBE) cells were expanded and cultured according to published methods (Neuberger et al., Ch. 4 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221983(US9303035, 6.1)
Affinity DataIC50: 0.240nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221992(US9303035, 12.2)
Affinity DataIC50: 0.240nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM50566263(CHEMBL4776653)
Affinity DataEC50: <0.310nMAssay Description:Potentiation of CFTR F508del mutant (unknown origin) expressed in human CFBE41o- cells co-expressing YFP incubated for 10 mins by halide potentiator ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2022
Entry Details Article
PubMed
TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221989(US9303035, 11a)
Affinity DataIC50: 0.310nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM301470(4-amino-5-[2-(difluoromethyl)pyrimidin-5-yl]-7-{1-...)
Affinity DataEC50:  0.400nMAssay Description:Primary cystic fibrosis human bronchial epithelial (CF hBE) cells were expanded and cultured according to published methods (Neuberger et al., Ch. 4 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM50595765(CHEMBL5178232)
Affinity DataEC50:  0.400nMAssay Description:Modulation of homozygous F508del/F508del CFTR mutant in HBE cells incubated for 18 to 24 hrs by trans-epithelial current clamp assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/22/2023
Entry Details
PubMed
TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM301443(4-amino-5-[2-(difluoromethyl)pyrimidin-5-yl]-7-{[1...)
Affinity DataEC50:  0.410nMAssay Description:Fischer rat thyroid (FRT) cell lines stably expressing recombinant F508del V470 CFTR and halide-sensitive yellow fluorescent protein (Pedemonte et al...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM301429(US10131670, Example 13 | 4-amino-7-{1-[1-(2-fluoro...)
Affinity DataEC50:  0.420nMAssay Description:Primary cystic fibrosis human bronchial epithelial (CF hBE) cells were expanded and cultured according to published methods (Neuberger et al., Ch. 4 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM301433(BDBM301434 | 4-amino-7-{1-[1-(2,4-difluorophenyl)-...)
Affinity DataEC50:  0.420nMAssay Description:Primary cystic fibrosis human bronchial epithelial (CF hBE) cells were expanded and cultured according to published methods (Neuberger et al., Ch. 4 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM50516910(CHEMBL4558190)
Affinity DataEC50:  0.5nMAssay Description:Corrector activity at CFTR F508del mutant (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM50595762(CHEMBL5193680)
Affinity DataEC50:  0.510nMAssay Description:Modulation of homozygous F508del/F508del CFTR mutant in HBE cells incubated for 18 to 24 hrs by trans-epithelial current clamp assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/22/2023
Entry Details
PubMed
TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221993(US9303035, 12.4)
Affinity DataIC50: 0.540nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM301431(BDBM301432 | US10131670, Example 14 | 4-amino-7-{1...)
Affinity DataEC50:  0.560nMAssay Description:Fischer rat thyroid (FRT) cell lines stably expressing recombinant F508del V470 CFTR and halide-sensitive yellow fluorescent protein (Pedemonte et al...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM301433(BDBM301434 | 4-amino-7-{1-[1-(2,4-difluorophenyl)-...)
Affinity DataEC50:  0.560nMAssay Description:Fischer rat thyroid (FRT) cell lines stably expressing recombinant F508del V470 CFTR and halide-sensitive yellow fluorescent protein (Pedemonte et al...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM301442(4-amino-7-{[1-(2-fluorophenyl)-1H-pyrazol-4-yl]met...)
Affinity DataEC50:  0.570nMAssay Description:Fischer rat thyroid (FRT) cell lines stably expressing recombinant F508del V470 CFTR and halide-sensitive yellow fluorescent protein (Pedemonte et al...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221967(US9303035, 2.9)
Affinity DataIC50: 0.590nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221990(US9303035, 12)
Affinity DataIC50: 0.600nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221985(US9303035, 7.1a)
Affinity DataIC50: 0.610nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM301429(US10131670, Example 13 | 4-amino-7-{1-[1-(2-fluoro...)
Affinity DataEC50:  0.620nMAssay Description:Fischer rat thyroid (FRT) cell lines stably expressing recombinant F508del V470 CFTR and halide-sensitive yellow fluorescent protein (Pedemonte et al...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221994(US9303035, 12.5)
Affinity DataIC50: 0.620nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221970(US9303035, 3.2)
Affinity DataIC50: 0.640nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM301438(4-amino-7-{(1R)-1-[1-(2,4-difluorophenyl)-1H-pyraz...)
Affinity DataEC50:  0.660nMAssay Description:Primary cystic fibrosis human bronchial epithelial (CF hBE) cells were expanded and cultured according to published methods (Neuberger et al., Ch. 4 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM50595764(CHEMBL5178488)
Affinity DataEC50:  0.660nMAssay Description:Modulation of homozygous F508del/F508del CFTR mutant in HBE cells incubated for 18 to 24 hrs by trans-epithelial current clamp assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/22/2023
Entry Details
PubMed
TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221969(US9303035, 3.1)
Affinity DataIC50: 0.700nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM50595761(CHEMBL5202275)
Affinity DataEC50:  0.800nMAssay Description:Modulation of homozygous F508del/F508del CFTR mutant in HBE cells incubated for 18 to 24 hrs by trans-epithelial current clamp assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/22/2023
Entry Details
PubMed
TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM50595763(CHEMBL5186971)
Affinity DataEC50:  0.840nMAssay Description:Modulation of homozygous F508del/F508del CFTR mutant in HBE cells incubated for 18 to 24 hrs by trans-epithelial current clamp assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/22/2023
Entry Details
PubMed
TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM301442(4-amino-7-{[1-(2-fluorophenyl)-1H-pyrazol-4-yl]met...)
Affinity DataEC50:  0.860nMAssay Description:Primary cystic fibrosis human bronchial epithelial (CF hBE) cells were expanded and cultured according to published methods (Neuberger et al., Ch. 4 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM50595766(CHEMBL5171054)
Affinity DataEC50:  0.900nMAssay Description:Modulation of homozygous F508del/F508del CFTR mutant in HBE cells incubated for 18 to 24 hrs by trans-epithelial current clamp assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/22/2023
Entry Details
PubMed
TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM301443(4-amino-5-[2-(difluoromethyl)pyrimidin-5-yl]-7-{[1...)
Affinity DataEC50:  1.05nMAssay Description:Primary cystic fibrosis human bronchial epithelial (CF hBE) cells were expanded and cultured according to published methods (Neuberger et al., Ch. 4 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM50566262(CHEMBL4799994)
Affinity DataEC50:  1.10nMAssay Description:Potentiation of CFTR F508del mutant (unknown origin) expressed in human CFBE41o- cells co-expressing YFP incubated for 10 mins by halide potentiator ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2022
Entry Details Article
PubMed
TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM301463(US10131670, Example 87 | BDBM301464 | {1-[1-(2-Flu...)
Affinity DataEC50:  1.53nMAssay Description:Primary cystic fibrosis human bronchial epithelial (CF hBE) cells were expanded and cultured according to published methods (Neuberger et al., Ch. 4 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221952(US9303035, 1.2)
Affinity DataIC50: 1.58nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM301435(4-amino-7-{1-[3-(2-fluorophenyl)-1,2-oxazol-5-yl]e...)
Affinity DataEC50:  1.67nMAssay Description:Primary cystic fibrosis human bronchial epithelial (CF hBE) cells were expanded and cultured according to published methods (Neuberger et al., Ch. 4 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM301449(US10131670, Example 82 | 7-{1-[1-(2-fluorophenyl)-...)
Affinity DataEC50:  1.88nMAssay Description:Fischer rat thyroid (FRT) cell lines stably expressing recombinant F508del V470 CFTR and halide-sensitive yellow fluorescent protein (Pedemonte et al...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221958(US9303035, 1.26)
Affinity DataIC50: 1.90nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221996(US9303035, 14)
Affinity DataIC50: 1.96nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM50035582(CHEMBL3357142)
Affinity DataEC50:  2nMAssay Description:Potentiation of human CFTR F508del mutant expressed in mouse NIH-3T3 cells after 30 mins by fluorescent voltage sensing optical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2016
Entry Details Article
PubMed
TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM301431(BDBM301432 | US10131670, Example 14 | 4-amino-7-{1...)
Affinity DataEC50:  2nMAssay Description:Primary cystic fibrosis human bronchial epithelial (CF hBE) cells were expanded and cultured according to published methods (Neuberger et al., Ch. 4 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM301449(US10131670, Example 82 | 7-{1-[1-(2-fluorophenyl)-...)
Affinity DataEC50:  2nMAssay Description:Primary cystic fibrosis human bronchial epithelial (CF hBE) cells were expanded and cultured according to published methods (Neuberger et al., Ch. 4 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM301451(US10131670, Example 60 | 7-{1-[1-(2,4-difluorophen...)
Affinity DataEC50:  2nMAssay Description:Primary cystic fibrosis human bronchial epithelial (CF hBE) cells were expanded and cultured according to published methods (Neuberger et al., Ch. 4 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM50032694(CHEMBL3354672)
Affinity DataEC50:  2.10nMAssay Description:Inhibition of CFTR F508 deletion mutant (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/15/2024
Entry Details
PubMed
TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM301421(4-amino-7-{1-[1-(2-fluorophenyl)-1H-1,2,3-triazol-...)
Affinity DataEC50:  2.13nMAssay Description:Fischer rat thyroid (FRT) cell lines stably expressing recombinant F508del V470 CFTR and halide-sensitive yellow fluorescent protein (Pedemonte et al...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM50566258(CHEMBL4787310)
Affinity DataEC50:  2.80nMAssay Description:Potentiation of CFTR F508del mutant (unknown origin) expressed in human CFBE41o- cells co-expressing YFP incubated for 10 mins by halide potentiator ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2022
Entry Details Article
PubMed
TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM50035581(CHEMBL3357141)
Affinity DataEC50:  3nMAssay Description:Potentiation of human CFTR F508del mutant expressed in mouse NIH-3T3 cells after 30 mins by fluorescent voltage sensing optical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2016
Entry Details Article
PubMed
TargetCystic fibrosis transmembrane conductance regulator(Human)
Cystic Fibrosis Foundation Therapeutics

US Patent
LigandPNGBDBM50032693(CHEBI:66901 | Ivacaftor | Kalydeco | VX-770)
Affinity DataEC50:  3nMAssay Description:Potentiation of human CFTR F508del mutant expressed in mouse NIH-3T3 cells after 30 mins by fluorescent voltage sensing optical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2016
Entry Details Article
PubMedPDB3D3D Structure (crystal)
Displayed 1 to 50 (of 1808 total ) | Next | Last >>
Jump to: